All posts

Follow Us

LinkedInInstagramX
Annual ResultsArchiveLast updated 18 November 20263 min read

Novateor (NOVATEOR) Q4 FY26 Profit Jumps 140% Despite a 31% Revenue Drop

The oral care firm's Q4 FY26 profit surged on lower costs and other income, but a qualified audit opinion and falling sales raise questions about its core business health.

By Anant Kacholia, HexaWealth Research · Created 18 November 2026

Novateor Research Laboratories reported a 140% jump in Q4 FY26 net profit even as revenue fell 31% year-on-year. The profit growth was driven by a sharp fall in expenses and steady other income, but the auditor flagged concerns over interest income recognition.

For a small FMCG player like Novateor Research Laboratories, the quarterly numbers often tell two different stories. The March 2026 quarter delivered a stark split: a sharp drop in sales but a dramatic leap in profitability.

Revenue for Q4 FY26 fell 31% year-on-year to ₹1.36 crore. Sequentially, the drop was even steeper at 45% from the September 2025 quarter. Yet, net profit soared 140% to ₹0.12 crore. The net profit margin expanded to 8.8%, a significant 630 basis point improvement from the same quarter last year.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ4 FY24 0.85, Q2 FY25 0.79, Q4 FY25 1.98, Q2 FY26 2.47, Q4 FY26 1.36. Q4 FY24 0.04, Q2 FY25 0.03, Q4 FY25 0.05, Q2 FY26 -0.02, Q4 FY26 0.12-4-2024Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 0.85
  • Revenue (₹ Cr), Q2 FY25: 0.79
  • Revenue (₹ Cr), Q4 FY25: 1.98
  • Revenue (₹ Cr), Q2 FY26: 2.47
  • Revenue (₹ Cr), Q4 FY26: 1.36
  • Profit (₹ Cr), Q4 FY24: 0.04
  • Profit (₹ Cr), Q2 FY25: 0.03
  • Profit (₹ Cr), Q4 FY25: 0.05
  • Profit (₹ Cr), Q2 FY26: -0.02
  • Profit (₹ Cr), Q4 FY26: 0.12

Revenue (₹ Cr)

Revenue (₹ Cr)Q4 FY24 0.85, Q2 FY25 0.79, Q4 FY25 1.98, Q2 FY26 2.47, Q4 FY26 1.3601234Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Revenue (₹ Cr), Q4 FY24: 0.85
  • Revenue (₹ Cr), Q2 FY25: 0.79
  • Revenue (₹ Cr), Q4 FY25: 1.98
  • Revenue (₹ Cr), Q2 FY26: 2.47
  • Revenue (₹ Cr), Q4 FY26: 1.36

Profit (₹ Cr)

Profit (₹ Cr)Q4 FY24 0.04, Q2 FY25 0.03, Q4 FY25 0.05, Q2 FY26 -0.02, Q4 FY26 0.12-2-1012Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Profit (₹ Cr), Q4 FY24: 0.04
  • Profit (₹ Cr), Q2 FY25: 0.03
  • Profit (₹ Cr), Q4 FY25: 0.05
  • Profit (₹ Cr), Q2 FY26: -0.02
  • Profit (₹ Cr), Q4 FY26: 0.12

Net Profit Margin (%)

Net Profit Margin (%)Q4 FY24 4.7, Q2 FY25 3.8, Q4 FY25 2.5, Q2 FY26 -0.8, Q4 FY26 8.8-20%-10%0%10%20%Q4 '24Q2 '25Q4 '25Q2 '26Q4 '26
  • Net Profit Margin (%), Q4 FY24: 4.7
  • Net Profit Margin (%), Q2 FY25: 3.8
  • Net Profit Margin (%), Q4 FY25: 2.5
  • Net Profit Margin (%), Q2 FY26: -0.8
  • Net Profit Margin (%), Q4 FY26: 8.8
MetricCurrentQ4 FY26Same quarter LYQ4 FY25
Revenue (₹ Cr)
1.36YoY -31%
1.98
Profit (₹ Cr)
0.12YoY +140%
0.05
Net Profit Margin (%)
8.8YoY +252%
2.5

Why Profit Rose as Sales Fell

The profit jump was not driven by operating strength. According to analysis by Newboard.in, the company's core operations have lost money for years. The reported profit rests on interest income from loans. In FY26, this other income of ₹0.48 crore exceeded the profit before tax of ₹0.11 crore.

Total expenses fell 46% sequentially, mirroring the revenue decline. This suggests costs are variable and tied directly to sales volume. With lower sales, expenses on raw materials and manufacturing dropped, providing a temporary lift to the bottom line.

Live Chart

· NOVATEOR

(BSE)

ISIN: INE08JY01013

The Auditor's Red Flag

The financials come with a major caveat. The auditor gave a qualified opinion, citing unverifiable inventory and ₹1.66 crore of disputed interest income recognized despite legal uncertainty, as reported by mCapital.in. This means the reported profit improvement relies heavily on income the auditor says may not be received.

Without this disputed interest, the company's core oral care business—selling SmileShine teeth whitening products—remains loss-making. The FY26 annual operating margin was -2.7%.

A Shrinking Top Line and Future Plans

The revenue decline points to challenges in scaling the branded business. Management has stated plans to expand into cosmetics and healthcare and move to a semi-automated plant in Sanand. However, Newboard.in notes these plans are repeated without firm dates, and the company reported no R&D expenditure in FY26.

The outlook is clouded. For the half-year ended September 2026, mCapital.in estimates the revenue run-rate is tracking about 30% below FY26 levels, with operating losses deepening. The company's valuation reflects skepticism, trading at a P/E of 188, a 394% premium to its industry.

Key Points

  • Novateor's Q4 FY26 net profit jumped 140% year-on-year to ₹0.12 crore, but revenue fell 31% to ₹1.36 crore.
  • The profit surge was aided by a proportional drop in expenses and reliance on other income, which the auditor flagged as disputed.
  • The company's core SmileShine oral care business continues to report operating losses, with an annual margin of -2.7% for FY26.
  • Future growth plans for capacity expansion and new categories lack concrete timelines and R&D backing.

Hexa Perspective

The quarter underscores a business where reported profitability is structurally detached from operating performance. The profit jump is a function of lower sales volume reducing variable costs, not operational efficiency or pricing power.

The qualified audit opinion on interest income is a critical overhang, making the bottom line an unreliable indicator of financial health. For the story to change, Novateor needs its branded sales to reach a scale that covers fixed costs, a milestone that appears distant given the declining revenue trajectory.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Novateor Research Laboratories (NOVATEOR) Q4 FY26 results, revenue and profits.

Frequently asked questions

What were Novateor Research Laboratories' Q4 FY26 results?
Novateor reported Q4 FY26 revenue of ₹1.36 crore, a 31% decline from the same quarter last year. However, net profit jumped 140% year-on-year to ₹0.12 crore, driven by a sharp fall in total expenses and steady other income.
Why did Novateor's Q4 FY26 profit jump 140% despite lower sales?
Novateor's profit surged because total expenses fell 46% sequentially, closely tracking the 45% drop in revenue. Furthermore, the company's profit relies significantly on other income, primarily interest on loans, which contributed ₹0.48 crore for the full year FY26.
What was the auditor's qualification in Novateor's FY26 results?
The auditor issued a qualified opinion, flagging that ₹1.66 crore of interest income was recognized despite being under dispute and not yet received. The auditor also cited issues with unverifiable inventory and the absence of a gratuity provision.
What is Novateor Research Laboratories' operating margin?
Novateor's core operations are loss-making. For the full year FY26, the company reported an operating profit margin of -2.7%, meaning costs exceeded sales. Analysis by Newboard.in shows the operating line has been negative for years.
What are Novateor's expansion plans for FY27?
Management has stated intentions to expand into cosmetics and healthcare products and move manufacturing to a semi-automated plant in Sanand, GIDC. However, these plans are repeated without specific dates, and the company reported no R&D expenditure in FY26.
How did Novateor's stock price react to the Q4 FY26 results?
Available data from TickJournal.com shows the quarterly result announcement on May 30, 2026, had a listed price impact of 0.00%, indicating no significant immediate market reaction to the earnings release.
What is the sales outlook for Novateor's SmileShine products?
The sales trajectory is concerning. For the half-year ended September 2026, mCapital.in estimates the annualized revenue run-rate is about 30% below FY26's ₹3.83 crore, implying a significant decline for the SmileShine portfolio.
Does Novateor have any institutional investor holding?
As of September 2026, data from Alfafinder.com shows foreign and domestic institutional investors held 0.00% stake in Novateor. The promoter holding was 50.75%, with the remainder held by the public and others.
What is Novateor's debt-to-equity ratio?
Novateor maintains a conservative balance sheet with a low debt burden. As of March 2026, the company's debt-to-equity ratio was 0.13, indicating most of its capital is funded by equity.
What was Novateor's net profit in H2 FY26?
Novateor Research Laboratories reported a net profit of ₹0.1 crore for the second half (H2) of FY26, which covers the quarters ended September 2025 and March 2026, as per data from Alfafinder.com.
Novateor Research Laboratories H2 FY26 results?
For H2 FY26 (the half-year ending March 2026), Novateor reported revenue from operations of ₹1.4 crore, down 30% year-on-year, and a net profit of ₹0.1 crore, according to Alfafinder.com.
Novateor Research Laboratories Q4 FY26 results August 2026?
Novateor's Q4 FY26 (March 2026 quarter) results were announced on May 30, 2026. The company reported revenue of ₹1.36 crore and a net profit of ₹0.12 crore for the quarter.